Sino Biopharmaceutical Limited (SMZ1) - Total Assets
Based on the latest financial reports, Sino Biopharmaceutical Limited (SMZ1) holds total assets worth €74.89 Billion EUR as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Sino Biopharmaceutical Limited - Total Assets Trend (2013–2024)
This chart illustrates how Sino Biopharmaceutical Limited's total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Sino Biopharmaceutical Limited - Asset Composition Analysis
Current Asset Composition (December 2024)
Sino Biopharmaceutical Limited's total assets of €74.89 Billion consist of 37.7% current assets and 62.3% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 14.6% |
| Accounts Receivable | €4.31 Billion | 6.6% |
| Inventory | €2.37 Billion | 3.6% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €2.15 Billion | 3.3% |
| Goodwill | €915.69 Million | 1.4% |
Asset Composition Trend (2013–2024)
This chart illustrates how Sino Biopharmaceutical Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Sino Biopharmaceutical Limited's current assets represent 37.7% of total assets in 2024, a decrease from 58.5% in 2013.
- Cash Position: Cash and equivalents constituted 14.6% of total assets in 2024, down from 29.9% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, an increase from 0.0% in 2013.
- Asset Diversification: The largest asset category is accounts receivable at 6.6% of total assets.
Sino Biopharmaceutical Limited Competitors by Total Assets
Key competitors of Sino Biopharmaceutical Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $1.48 Billion |
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
WOOJUNG BIO Inc
KQ:215380
|
Korea | ₩89.80 Billion |
|
Zelluna ASA
OL:ZLNA
|
Norway | Nkr103.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
Sino Biopharmaceutical Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.36 | 1.15 | 3.27 |
| Quick Ratio | 1.28 | 1.07 | 3.09 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €8.97 Billion | €3.27 Billion | €23.87 Billion |
Sino Biopharmaceutical Limited - Advanced Valuation Insights
This section examines the relationship between Sino Biopharmaceutical Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.36 |
| Latest Market Cap to Assets Ratio | 0.20 |
| Asset Growth Rate (YoY) | 2.8% |
| Total Assets | €65.41 Billion |
| Market Capitalization | $13.26 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Sino Biopharmaceutical Limited's assets below their book value (0.20x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Sino Biopharmaceutical Limited's assets grew by 2.8% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Sino Biopharmaceutical Limited (2013–2024)
The table below shows the annual total assets of Sino Biopharmaceutical Limited from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €65.41 Billion | +2.84% |
| 2023-12-31 | €63.60 Billion | -0.72% |
| 2022-12-31 | €64.06 Billion | +5.82% |
| 2021-12-31 | €60.54 Billion | +28.24% |
| 2020-12-31 | €47.21 Billion | -19.02% |
| 2019-12-31 | €58.30 Billion | +17.11% |
| 2018-12-31 | €49.78 Billion | +137.78% |
| 2017-12-31 | €20.94 Billion | +13.83% |
| 2016-12-31 | €18.39 Billion | +11.58% |
| 2015-12-31 | €16.48 Billion | +16.37% |
| 2014-12-31 | €14.16 Billion | +42.08% |
| 2013-12-31 | €9.97 Billion | -- |
About Sino Biopharmaceutical Limited
Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injecti… Read more